[go: up one dir, main page]

SG10201405408YA - Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases - Google Patents

Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Info

Publication number
SG10201405408YA
SG10201405408YA SG10201405408YA SG10201405408YA SG10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA SG 10201405408Y A SG10201405408Y A SG 10201405408YA
Authority
SG
Singapore
Prior art keywords
mcp
treatment
pharmaceutical composition
inflammatory diseases
mediated inflammatory
Prior art date
Application number
SG10201405408YA
Inventor
Angelo Guglielmotti
Beatrice Garrone
Alessandro Ble
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of SG10201405408YA publication Critical patent/SG10201405408YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SG10201405408YA 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases SG10201405408YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09425368 2009-09-23

Publications (1)

Publication Number Publication Date
SG10201405408YA true SG10201405408YA (en) 2014-10-30

Family

ID=41722750

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012010302A SG178414A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
SG10201405408YA SG10201405408YA (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012010302A SG178414A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Country Status (26)

Country Link
US (1) US9492542B2 (en)
EP (1) EP2480224B1 (en)
JP (2) JP2013505278A (en)
KR (1) KR101774402B1 (en)
CN (1) CN102573827B (en)
AR (1) AR078307A1 (en)
AU (1) AU2010297405B2 (en)
BR (1) BR112012006149A2 (en)
CA (1) CA2760180C (en)
CY (1) CY1119125T1 (en)
DK (1) DK2480224T3 (en)
EA (1) EA021485B1 (en)
ES (1) ES2637024T3 (en)
GE (1) GEP20146067B (en)
HR (1) HRP20171209T1 (en)
HU (1) HUE033102T2 (en)
IL (1) IL218001A (en)
LT (1) LT2480224T (en)
MX (1) MX347957B (en)
PL (1) PL2480224T3 (en)
PT (1) PT2480224T (en)
SG (2) SG178414A1 (en)
SI (1) SI2480224T1 (en)
SM (1) SMT201700330T1 (en)
UA (1) UA108742C2 (en)
WO (1) WO2011036047A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2714436C (en) 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
JP5509102B2 (en) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ Novel 1-benzyl-3-hydroxymethylindazole derivatives and their use in the treatment of diseases based on the expression of MCP-1 and CX3CR1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US11221321B2 (en) * 2019-05-29 2022-01-11 Imam Abdulrahman Bin Faisal University Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof
US11753382B2 (en) 2019-06-25 2023-09-12 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
JP2023082437A (en) * 2021-12-02 2023-06-14 学校法人東京薬科大学 Compositions for suppressing inflammation involving the recruitment of immune cells by CCL8
CN116688135B (en) * 2023-07-28 2024-10-29 四川大学华西医院 Osteoarthritis drug treatment composition and preparation method and application thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK356085A (en) 1984-08-06 1986-02-07 Upjohn Co PURE INHIBITION OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
IT1230441B (en) 1989-02-07 1991-10-23 Acraf ETHERS OF THE INDAZOLE SERIES
CA2023099A1 (en) 1989-09-04 1991-03-05 Quirico Branca Amino acid derivatives
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
TW198712B (en) 1991-04-17 1993-01-21 Hoffmann La Roche
IT1253703B (en) 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca USE OF ALCANOIC ACID METHODS OF INDAZOLE TO PREPARE AN ACTIVE DRUG IN THE TREATMENT OF AUTOIMMUNITARY DISEASES
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IT1276031B1 (en) 1995-10-31 1997-10-24 Angelini Ricerche Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
SE9600120D0 (en) 1996-01-15 1996-01-15 Astra Ab Novel medical use
IT1293795B1 (en) 1997-07-28 1999-03-10 Angelini Ricerche Spa DRUG ACTIVE IN REDUCING THE PRODUCTION OF MCP-1 PROTEIN
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
US20030073705A1 (en) 2001-05-14 2003-04-17 Shahnaz Shahinfar Method of treatment
US20030060502A1 (en) 2001-09-19 2003-03-27 Francois Mach Treatment of diabetes with statins (HMG-COa reductase inhibitors)
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20070060549A1 (en) 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
WO2006046528A1 (en) 2004-10-29 2006-05-04 Kowa Co., Ltd. Therapeutic agent for glomerular disease
EP2526937A1 (en) 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
WO2008084504A2 (en) 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5509102B2 (en) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ Novel 1-benzyl-3-hydroxymethylindazole derivatives and their use in the treatment of diseases based on the expression of MCP-1 and CX3CR1
CA2714436C (en) 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
LT2254869T (en) 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 and p40

Also Published As

Publication number Publication date
MX347957B (en) 2017-05-16
SG178414A1 (en) 2012-03-29
IL218001A (en) 2015-10-29
EA201270449A1 (en) 2012-08-30
CA2760180A1 (en) 2011-03-31
IL218001A0 (en) 2012-04-30
CN102573827B (en) 2016-08-31
CA2760180C (en) 2017-07-25
EA021485B1 (en) 2015-06-30
EP2480224A1 (en) 2012-08-01
GEP20146067B (en) 2014-03-25
PL2480224T3 (en) 2017-10-31
KR101774402B1 (en) 2017-09-04
LT2480224T (en) 2017-08-25
MX2012003485A (en) 2012-04-19
AU2010297405B2 (en) 2016-05-26
WO2011036047A1 (en) 2011-03-31
SMT201700330T1 (en) 2017-09-07
JP2013505278A (en) 2013-02-14
SI2480224T1 (en) 2017-10-30
KR20120090988A (en) 2012-08-17
JP6122470B2 (en) 2017-04-26
HUE033102T2 (en) 2017-11-28
CY1119125T1 (en) 2018-02-14
DK2480224T3 (en) 2017-09-04
CN102573827A (en) 2012-07-11
BR112012006149A2 (en) 2016-06-28
HRP20171209T1 (en) 2017-10-20
AR078307A1 (en) 2011-10-26
US9492542B2 (en) 2016-11-15
EP2480224B1 (en) 2017-05-24
JP2016028026A (en) 2016-02-25
US20120220636A1 (en) 2012-08-30
AU2010297405A1 (en) 2012-03-01
UA108742C2 (en) 2015-06-10
PT2480224T (en) 2017-07-18
ES2637024T3 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
IL257581A (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
PT2482812T (en) Therapeutic uses of pharmaceutical compositions
IL200368A0 (en) Treatment of diseases characterized by inflammation
PT3470063T (en) Pharmaceutical compositions for the treatment of cftr mediated diseases
IL216618A0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
PT2429507T (en) Phosphate-free pharmaceutical composition for the treatment of glaucoma
ZA200905364B (en) Treatment of diseases characterized by inflammation
IL218001A0 (en) Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
HUE051538T2 (en) Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
IL200753A (en) Pharmaceutical composition comprising ib-meca for the treatment of psoriasis
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
GB0819446D0 (en) Treatment of inflammatory disorders
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases